Last updated October 21, 2026. Approval line checked October 21, 2026. Compounding sources checked October 10, 2026.
FDA status
Not approved
Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.
FDA primary source on fileBy signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Human Observational. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 3/5. 1,031 PubMed citations indexed.
Endogenous 43-aa cytoplasmic peptide sequestering G-actin to promote cell migration; upregulates anti-apoptotic pathways and VEGF for cardiac and wound tissue repair.
What the literature studies
Tissue Repair & Cardiac Protection
Evidence tier
Human Observational
Compounding record
Status not verified
Status not verified. Status not verified. Exact FDA substance context: FDA names the thymosin beta-4 fragment LKKTETQ (TB-500), not this full-length 43-amino-acid peptide. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source checked October 10, 2026. This compounding label is separate from the approval line above.
Full sequence distinct from TB-500 fragment; WADA-banned; pro-angiogenic activity contraindicated in cancer.
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.